A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
Clinical trial NCT01723826 · COMPLETED
Trial details
- NCT number
- NCT01723826
- Sponsor
- Genentech, Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2012-12-07
- Primary completion
- 2017-02-08
- Enrollment
- 360
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.